Table 1.
Patient clinical and disease characteristics
| No. of patients | % of total* | |
|---|---|---|
| Sex | ||
| Male | 293 | 86% |
| Female | 47 | 14% |
| Race/ethnicity | ||
| White | 295 | 87% |
| Black | 18 | 5% |
| Hispanic | 9 | 3% |
| Other/Unknown | 18 | 5% |
| Subsite | ||
| Base of tongue | 162 | 48% |
| Tonsil | 166 | 49% |
| Pharyngeal wall | 8 | 2% |
| Soft palate | 4 | 1% |
| T stage | ||
| T1 | 81 | 24% |
| T2 | 147 | 43% |
| T3 | 62 | 18% |
| T4 | 50 | 15% |
| N stage | ||
| N0 | 25 | 7% |
| N1 | 71 | 21% |
| N2 | 236 | 69% |
| N3 | 8 | 2% |
| AJCC stage | ||
| I | 3 | 1% |
| II | 12 | 4% |
| III | 62 | 18% |
| IV | 263 | 77% |
| Chemotherapy regimen | ||
| Cisplatin | 183 | 54% |
| Cisplain+bevacizumab | 37 | 11% |
| Cetuximab | 43 | 13% |
| Carboplatin+fluorouracil | 35 | 10% |
| Other | 25 | 7% |
| None | 17 | 5% |
*
Percentages may not add up to 100% because of rounding.